此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis

2026年8月19日 更新者:Guangdong Hengrui Pharmaceutical Co., Ltd

A Multicenter, Randomized, Double-blind, Parallel-group Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Moderate to Severe Plaque Psoriasis

This study is a randomized, double-blind, multi-center, parallel, phase II clinical trial, aiming to evaluate the efficacy and safety of SHR-1139 injection for adult patients with psoriasis. The trial includes a 4-week screening period, a 52-week treatment period, and a 12-week safety follow-up period. Approximately 60 patients with psoriasis are expected to participate.

研究概览

研究类型

介入性

注册 (估计的)

60

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Guangzhou
      • Guangzhou、Guangzhou、中国、510091
        • 招聘中
        • Dermatology Hospital Hospital of Southern Medical University
        • 首席研究员:
          • Bin Yang
        • 首席研究员:
          • Xiaohua Wang

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. During the screening process, the body mass index (BMI = weight (kg) / height^2 (m^2)) was ≥ 18 kg/m^2;
  2. History of plaque psoriasis for more than 6 months before randomization;
  3. The PASI score, sPGA score, and BSA at the screening and baseline required certain requirements;
  4. Participants suitable for phototherapy or systemic psoriasis treatment for moderate to severe plaque psoriasis;
  5. Participants voluntarily signed the informed consent before any procedures related to the study, could communicate smoothly with the researchers, understood and were willing to strictly follow the requirements of this clinical study protocol to complete the study;
  6. Female participants with reproductive capacity or their male partners with reproductive capacity, starting from the date of signing the informed consent until 72 weeks after the last medication, had no plans for pregnancy, sperm donation, or egg donation, and voluntarily took effective contraceptive measures. The pregnancy test results of female participants during the screening period and before random administration should be negative, and must be non-lactating.

Exclusion Criteria:

-

The following conditions or diseases must be absent:

  1. The diagnosed psoriasis at the screening or baseline stage is not chronic plaque-type psoriasis;
  2. Has drug-induced psoriasis;
  3. Has other skin problems that the investigator considers would interfere with the assessment of psoriasis;
  4. Has concurrent other active autoimmune diseases, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, multiple sclerosis or other central demyelinating diseases, primary Sjögren's syndrome, etc.;

Using the following drugs or participating in clinical studies:

  1. During the pre-baseline period, other biological agents had been used but did not meet the washout requirements.
  2. Has used drugs targeting the same target before the screening;
  3. Has received systemic psoriasis treatment drugs within the specified period before the baseline;
  4. Has received topical psoriasis treatment drugs within the specified period before the baseline;
  5. Has received phototherapy within the specified period before the baseline;
  6. Has participated in any clinical study of drugs or medical devices within 3 months before the baseline or within the drug's half-life period;

Important conditions or underlying diseases that affect safety:

  1. The participant has a history of lymphocytic proliferative diseases;
  2. The participant has had any active malignant tumor or history of malignant tumor within the previous 5 years before the screening;
  3. Has a history of moderate to severe congestive heart failure (NYHA cardiac function classification ≥ III) within 3 months before the screening, has experienced cardiovascular or cerebrovascular events or severe bleeding events, and the investigator considers this participant unsuitable for participating in the clinical study;
  4. Has had opportunistic infections or immunodeficiency diseases within the previous 6 months before the screening;
  5. Has had active infections requiring oral anti-infection treatment within 2 weeks before the baseline, or has had severe infections or systemic infections within 4 weeks before the baseline, requires intravenous anti-infection treatment or is hospitalized due to infection, or other chronic, recurrent, active infections that the investigator deems unsuitable for participation in this study;
  6. Has active tuberculosis (TB) or latent TB infection;
  7. Has human immunodeficiency virus antibody (HIV) positive at screening, or hepatitis C virus (HCV) antibody positive and further HCV-RNA quantitative positive; or hepatitis B surface antigen (HBsAg) positive; or HBsAg negative but HBcAb positive, and further HBV-DNA test positive; or Treponema pallidum specific antibody positive.
  8. Has severe, progressive, uncontrolled cardiovascular, liver, kidney, lung, gastrointestinal, hematopoietic system, endocrine, nervous system, mental system (such as depression, suicidal tendency and psychological disorders), skin and mucous membrane diseases, and other conditions that the investigator considers that the patient is not suitable to join this trial;
  9. Laboratory tests and/or 12-lead electrocardiogram (ECG) results are abnormal at screening:

General situation:

  1. Pregnant or lactating women;
  2. Allergic to any component of the test drug;
  3. Had a history of alcohol abuse or illegal drug use within the previous year before the screening;
  4. Had blood donation of approximately 500 mL within the previous 8 weeks before randomization or had a blood donation plan during the study;
  5. Had major surgery within the previous 8 weeks before screening, or had related surgery plans during the study;
  6. The investigator judges that there are other situations that affect the safety and efficacy evaluation of the test drug.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment group A: SHR-1139 injection/placebo
安慰剂
The SHR-1139 injection
实验性的:Treatment group B: SHR-1139 injection/placebo
安慰剂
The SHR-1139 injection

研究衡量的是什么?

主要结果指标

结果测量
大体时间
The proportion of participants who achieved a 100% improvement in the Psoriasis Area and Severity Index (PASI) score compared to the baseline by the 12th week (PASI 100).
大体时间:12th week
12th week

次要结果测量

结果测量
大体时间
The proportion of participants who achieved a minimum improvement of at least 75% in PASI compared to the baseline (PASI 75) in the 12th week;
大体时间:12th week
12th week
The proportion of participants who achieved a minimum improvement of at least 90% in PASI compared to the baseline (PASI 90) in the 12th week
大体时间:12th week
12th week
The proportion of participants who achieved a sPGA response of 0 or 1 (sPGA 0/1) as assessed by the static physician in the 12th week
大体时间:12th week
12th week
The proportion of participants who achieved a sPGA response of 0 (sPGA 0) in the 12th week
大体时间:12th week
12th week

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月4日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2027年10月31日

研究注册日期

首次提交

2026年7月17日

首先提交符合 QC 标准的

2026年7月17日

首次发布 (实际的)

2026年7月22日

研究记录更新

最后更新发布 (实际的)

2026年8月20日

上次提交的符合 QC 标准的更新

2026年8月19日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • SHR-1139-207

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅